Prevention and Medical Treatment of Pouchitis In Ulcerative Colitis.
Pouchitis
antibiotics
medical therapy
prevention
probiotics
remission.
Journal
Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
02
2019
revised:
04
06
2019
accepted:
12
06
2019
pubmed:
25
7
2019
medline:
21
8
2020
entrez:
24
7
2019
Statut:
ppublish
Résumé
Approximately 50% of patients who have undergone IPAA surgery for Ulcerative Colitis (UC) develop at least 1 episode of pouchitis. Patients with pouchitis have a wide range of symptoms, endoscopic and histologic features, disease course, and prognosis. To date, there are no universally accepted diagnostic criteria in terms of endoscopy and histology; though, semi-objective assessments to diagnose pouchitis in patients with ileal pouch- anal anastomosis (IPAA) have been proposed using composite scores such as the Pouchitis Triad, Heidelberg Pouchitis Activity Score and Pouchitis Disease Activity Index (PDAI). In a systematic review that included four randomized trials evaluating five agents for the treatment of acute pouchitis, ciprofloxacin was more effective at inducing remission as compared with metronidazole. Rifaximin was not more effective than placebo, while budesonide enemas and metronidazole were similarly effective for inducing remission of acute pouchitis. Patients with pouchitis relapsing more than three times per year are advised maintenance therapy, and guidelines recommend ciprofloxacin or the probiotic VSL#3. In patients with antibiotic-refractory pouchitis, secondary factors associated with an antibiotic-refractory course should be sought and treated. In this review, we will discuss the prevention and management of pouchitis in Ulcerative Colitis patients.
Identifiants
pubmed: 31333137
pii: CDT-EPUB-99875
doi: 10.2174/1389450120666190723130137
doi:
Substances chimiques
Anti-Bacterial Agents
0
Metronidazole
140QMO216E
Budesonide
51333-22-3
Ciprofloxacin
5E8K9I0O4U
Rifaximin
L36O5T016N
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1399-1408Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.